Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
Key result
Low-dose apixaban for primary VTE prevention in multiple myeloma patients receiving IMiDs resulted in 0 major hemorrhages and 0 VTE events over six months.
Why the study?
Immunomodulatory drugs (IMiDs) improve survival in multiple myeloma but increase rates of venous thromboembolism (VTE).
Does apixaban 2.5 mg twice daily safely prevent symptomatic VTE in multiple myeloma patients receiving immunomodulatory agents?
Comparison
Apixaban 2.5 mg orally twice daily for primary prevention of VTE
Design
Phase IV, single-arm pilot study
Authors
Discussion
Loading...
Member takes
Implication
May support low-dose apixaban VTE prophylaxis in IMiD-treated MM; hypothesis-generating, randomized trials needed.
Structured PICO
Does apixaban 2.5 mg twice daily safely prevent symptomatic VTE in multiple myeloma patients receiving immunomodulatory agents?
P
Population
50 patients with multiple myeloma receiving immunomodulatory agents, followed for six months.
I
Intervention
Apixaban 2.5 mg orally twice daily for six months
O
Outcome
Primary safety outcomes: rates of major haemorrhage and clinically relevant non-major haemorrhage over six months. Primary efficacy outcome: rate of symptomatic VTE over six months.safety
Low-dose apixaban (2.5 mg twice daily) appears safe and well-tolerated for primary VTE prevention in multiple myeloma patients on IMiDs, with no VTEs or major bleeds observed over 6 months in this pilot study.
Cite This Study
Cornell et al. (2020) studied multiple myeloma (n=50). apixaban was evaluated on rates of major haemorrhage and clinically relevant non-major haemorrhage (safety) and rate of symptomatic VTE (efficacy). Low-dose apixaban for primary VTE prevention in multiple myeloma patients receiving IMiDs resulted in 0 major hemorrhages and 0 VTE events over six months.